Buy Stocks Easy | About Us
July 4, 2020
Buy Stocks Easy | Online Stocks

MNOV


Buy MediciNova, Inc. Stock (symbol: MNOV) Easy Online

Company Name: MediciNova, Inc.

Symbol: MNOV

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2007

MNOV Current Share Price

Today's MNOV ( MediciNova, Inc. ) opening price: $7.1500

Yesterday's MNOV ( MediciNova, Inc. ) closing price: $7.1000

MediciNova, Inc. Stock ( symbol: MNOV ) Price Chart since IPO (2007):

12 Months MediciNova, Inc. Stock ( symbol: MNOV ) Price Chart

Popular Questions about MediciNova, Inc. Public Stock ( MNOV )

A: MediciNova, Inc. stock symbol (also called stock or share ticker) is MNOV

A: MediciNova, Inc. IPO (Initial Public Offering) took place on 2007

A: MediciNova, Inc.'s stock (MNOV symbol) price at ther IPO (initial Public Offering) was $7.1500

Q: Is MNOV stock worth buying at the moment?

A: The MNOV stock performance since 2019 are rather disappointing. If you had bought 1 share of MediciNova, Inc. stock (symbol: MNOV) at the beginning of 2019, at the opening share price of $9.0800, you would be left with exactly $7.1500 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy MediciNova, Inc. Stock Easy Online

MediciNova, Inc. Stock Ticker Price Chart since IPO:





MediciNova, Inc. Stock Price Yesterday



 


MediciNova, Inc. Stock Price – Last Week




 


MediciNova, Inc. Stock Price – Last Month




 


MediciNova, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/04/1956536/0/en/MediciNova-Announces-Additional-Analyses-from-Completed-Clinical-Trial-of-MN-166-ibudilast-in-ALS-Presented-at-the-30th-International-Symposium-on-ALS-MND-in-Perth-Australia.html
                            

                                
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia

                                
                                
LA JOLLA, Calif., Dec.  04, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/28/1936047/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Canada.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

                                
                                
LA JOLLA, Calif., Oct.  28, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/23/1933849/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-001-for-the-Treatment-of-NAFLD-and-NASH-in-Japan.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

                                
                                
LA JOLLA, Calif., Oct.  23, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/07/1926155/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-001-and-MN-002-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-in-Japan.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

                                
                                
LA JOLLA, Calif., Oct.  07, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922943/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-001-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-in-China.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

                                
                                
LA JOLLA, Calif., Sept.  30, 2019  (GLOBE NEWSWIRE) -- MediciNova, ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/29/1908784/0/en/MediciNova-to-Attend-the-Morgan-Stanley-Global-Healthcare-Conference-in-New-York.html
                            

                                
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York

                                
                                
LA JOLLA, Calif., Aug.  29, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4286979-medicinova-leading-pack-ms-subtype
                            

                                
MediciNova: Leading The Pack In An MS Subtype

                                
                                
MNOV has very strong phase 2b results in a subtype of MS for its le...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/04/1956536/0/en/MediciNova-Announces-Additional-Analyses-from-Completed-Clinical-Trial-of-MN-166-ibudilast-in-ALS-Presented-at-the-30th-International-Symposium-on-ALS-MND-in-Perth-Australia.html
                            

                                
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia

                                
                                
LA JOLLA, Calif., Dec.  04, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/28/1936047/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Canada.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

                                
                                
LA JOLLA, Calif., Oct.  28, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/23/1933849/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-001-for-the-Treatment-of-NAFLD-and-NASH-in-Japan.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

                                
                                
LA JOLLA, Calif., Oct.  23, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/07/1926155/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-001-and-MN-002-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-in-Japan.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan

                                
                                
LA JOLLA, Calif., Oct.  07, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922943/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-001-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis-in-China.html
                            

                                
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China

                                
                                
LA JOLLA, Calif., Sept.  30, 2019  (GLOBE NEWSWIRE) -- MediciNova, ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/29/1908784/0/en/MediciNova-to-Attend-the-Morgan-Stanley-Global-Healthcare-Conference-in-New-York.html
                            

                                
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York

                                
                                
LA JOLLA, Calif., Aug.  29, 2019  (GLOBE NEWSWIRE) -- MediciNova, I...


                            

                        
                    

                


                            

                    


                        
                            https://seekingalpha.com/article/4286979-medicinova-leading-pack-ms-subtype
                            

                                
MediciNova: Leading The Pack In An MS Subtype

                                
                                
MNOV has very strong phase 2b results in a subtype of MS for its le...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.